1,725,695 research outputs found
HB 3373
No full textHB 3373, Introduced version -- HB 3373-A, A-Engrossed version -- HB 3373-B, B-Engrossed version.Title from PDF caption (viewed on July 20, 2021).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may not be suitable for legal purposes.Mode of access: Internet from the Oregon Government Publications Collection.Text in English
[Veto of H. 3373, R-203]
No full textThis veto message from Governor Mark Sanford vetoes H. 3373, R-203 a bill providing an exemption to a statewide standard for a single county
Block Card 3373 Lagrange Street
No full textThis image was produced by the Auditor's Office in Lucas County, Ohio for tax assessment purposes. Associated dates are approximate. Descriptive terms related to this photograph include: commercial building | 3373 Lagrange Street (Toledo, Ohio) | doctors office | North Toledo (Toledo, Ohio) | Lagrange Area (Toledo, Ohio) | Doppkes St. Adalbert Additio
Block Card 3373 Blairmont Avenue
No full textThis image was produced by the Auditor's Office in Lucas County, Ohio for tax assessment purposes. Associated dates are approximate. Descriptive terms related to this photograph include: Ranch houses | 3373 Blairmont Avenue (Toledo, Ohio) | Dwelling | Heather Downs Second Addition (Toledo, Ohio) | South Toledo Area (Toledo, Ohio
Despacho n. 3373 de 13 de dezembro de 2013
No full textConcessão de licença para capcitação. Processo STJ n. 12750/2013. Despacho n. 3373/2013
Block Card 3373 Castle Boulevard
No full textThis image was produced by the Auditor's Office in Lucas County, Ohio for tax assessment purposes. Associated dates are approximate. Descriptive terms related to this photograph include: Cross gabled | Dwelling | 3373 Castle Boulevard (Toledo, Ohio) | Old West End (Toledo, Ohio) | Corydon Heights Addition (Toledo, Ohio) | Folk House Styl
Distribution of 3373 EST-SSRs motifs based on MISA script.
No full text<p>Distribution of 3373 EST-SSRs motifs based on MISA script.</p
Au/ZrO2: an efficient and reusable catalyst for the oxidative esterification of renewable furfural
No full textHighly dispersed gold based catalysts supported on zirconia were employed in the oxidative esterification of furfural by an efficient and sustainable process. Au/ZrO2 catalysts were calcined at different temperatures in order to modulate gold nanosize. A detailed characterization was carried out for the sake of ascertaining if micro structural changes occurred, and the size issue was discussed. Catalysts stability and recycling were investigated too, and the opportunity of reusability by thermal oxidation at a proper temperature was successfully proved. © 2012 Elsevier B.V
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
Full text link\ua9 The Author(s) 2024.Purpose: 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a phosphoramidate nucleotide analog of fluorodeoxyuridine (FUDR) designed to overcome these limitations and replace fluoropyrimidines such as 5-FU. Patients and methods: NUC-3373 was administered as monotherapy to patients with advanced solid tumors refractory to standard therapy via intravenous infusion either on Days 1, 8, 15 and 22 (Part 1) or on Days 1 and 15 (Part 2) of 28-day cycles until disease progression or unacceptable toxicity. Primary objectives were maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) and schedule of NUC-3373. Secondary objectives included pharmacokinetics (PK), and anti-tumor activity. Results: Fifty-nine patients received weekly NUC-3373 in 9 cohorts in Part 1 (n = 43) and 3 alternate-weekly dosing cohorts in Part 2 (n = 16). They had received a median of 3 prior lines of treatment (range: 0–11) and 74% were exposed to prior fluoropyrimidines. Four experienced dose-limiting toxicities: two Grade (G) 3 transaminitis; one G2 headache; and one G3 transient hypotension. Commonest treatment-related G3 adverse event of raised transaminases occurred in < 10% of patients. NUC-3373 showed a favorable PK profile, with dose-proportionality and a prolonged half-life compared to 5-FU. A best overall response of stable disease was observed, with prolonged progression-free survival. Conclusion: NUC-3373 was well-tolerated in a heavily pre-treated solid tumor patient population, including those who had relapsed on prior 5-FU. The MTD and RP2D was defined as 2500 mg/m2 NUC-3373 weekly. NUC-3373 is currently in combination treatment studies. Trial registration: Clinicaltrials.gov registry number NCT02723240. Trial registered on 8th December 2015. https://clinicaltrials.gov/study/NCT02723240
- …
